At a glance
- Originator Pharmacia Corporation
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 30 Jun 1995 New profile
- 30 Jun 1995 Preclinical development for Hyperlipidaemia in USA (Unknown route)